11/17/2005 12:34:04 PM ET


    O24 FIBROMYALGIA™ RECEIVES ENTHUSIASTIC RESPONSE TO LAUNCH OF NATIONAL FIBROMYALGIA
    ASSOCIATION AWARENESS CAMPAIGN
      
    FOR IMMEDIATE RELEASE

    Stock Symbol: OTC BB: SWME
    November 17, 2005

    O24 FIBROMYALGIA™ RECEIVES ENTHUSIASTIC RESPONSE TO LAUNCH OF NATIONAL FIBROMYALGIA
    ASSOCIATION AWARENESS CAMPAIGN

    Toronto, Canada - Swiss Medica, Inc. (OTC BB: SWME) today announced that response to new marketing
    initiatives has been very strong with over 20,000 requests for samples of O24 Fibromyalgia™ being received
    since November 11. Early demand for O24 Fibromyalgia™ at the retail level has also been very robust.

    O24 Fibromyalgia™ was featured in a National Fibromyalgia Association news bulletin on November 10 as the
    first product to receive the Association’s Seal of Approval. Since then, Swiss Medica has been contacted not only
    by thousands of people with the fibromyalgia condition, but by numerous hospitals, clinics and primary care
    physicians. O24 Fibromyalgia™ is the first clinically tested product specifically for fibromyalgia to be available in
    national pharmacies in the United States.

    Swiss Medica’s President and COO, Grant Johnson says “We have tremendous confidence in the efficacy of
    both O24 Pain Neutralizer and O24 Fibromyalgia™, and we know from experience that if people try the products,
    the vast majority will experience relief from pain and become loyal users of the product. We are very proud of our
    strategic alignment with the National Fibromyalgia Association and know that with their support, O24
    Fibromyalgia™ will bring relief to millions of fibromyalgia sufferers across North America.”

    O24 Fibromyalgia™ is available at leading retailers, including; Rite Aid, Longs and Albertsons. For detailed store
    locations, please visit www.O24zone.com.

    About Swiss Medica, Inc.

    Swiss Medica commercializes proprietary bioscience products that relieve chronic ailments. We increase our
    market share through focused distribution strategies in multiple sales channels. Swiss Medica's mission is to be a
    world leader in the commercialization of life enhancing bioscience products that improve quality of lives. Please
    visit our websites at www.swissmedica.com, www.O24zone.com and www.pmsescape.com.

    Swiss Medica's flagship product, the O24™ Pain Neutralizer, holds US Patent #6,444,238B1. The O24™ pain
    relief solution has been used, recommended and praised for its fast-acting and long-lasting benefits by
    healthcare professionals and athletes in the United States, Canada and in Europe. O24™ is widely available
    throughout the United States and Canada in leading pharmacies and other retailers. Customers can also visit
    www.O24zone.com, for ordering details and store locators for the nearest pharmacy.

    Swiss Medica is launching the patented O24 Fibromyalgia™ pain reliever (US Patent #6,444,238B1) over-the-
    counter in North American retailers in the fall of 2005. The National Fibromyalgia Association (NFA) recently
    awarded O24 Fibromyalgia™ their first NFA Seal of Approval. Upwards of 11 million Americans suffer from the
    long-term pain associated with fibromyalgia. In a randomized double blind clinical trial, more than 90 per cent of
    the patients who used O24 Fibromyalgia™ reported mild to markedly better improvement, versus only 7 per cent
    who used the placebo. Customers can visit www.O24zone.com for information on O24 Fibromyalgia™ and to
    order the product online.

    Swiss Medica also manufactures PMS Escape® which holds US Patent #'s 5760014 and 5612320. PMS
    Escape® is a specially formulated group of carbohydrates, vitamins and minerals, clinically proven to reduce
    changes in mood and appetite that women experience during the premenstrual period. Customers can also visit:
    www.pmsescape.com for additional information and ordering details.

    Forward-looking statements in this news release are made pursuant to the "Safe Harbor" provisions of the United
    States Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking
    statements involve risks and uncertainties, including, without limitation, risks relating to the ability to close
    transactions being contemplated, risks related to international sales and potential foreign currency exchange
    fluctuations, continued acceptance of Swiss Medica's products, increased levels of competition, technological
    changes, dependence on intellectual property rights and other risks detailed from time to time in Swiss Medica's
    periodic reports filed with the United States Securities and Exchange Commission and other regulatory
    authorities.

    For more information, please contact:

    Swiss Medica Inc.
    Investor Relations Contact:
    David Jones
    (866) 485-4243
    djones@swissmedica.com